DADC
SIOX

D.A. Davidson & Co’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

D.A. Davidson & Co’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-13
Closed -$1K – 2308
2015
Q3 		$1K Hold
13
– – ﹤0.01% 2162
2015
Q2 		$2K Buy
+13
New +$2.2K ﹤0.01% 2128

Other funds holding SIOX

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

D.A. Davidson & Co's SIOX Position: Q4 2015 in Review

D.A. Davidson & Co sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2015, closing a stake of 13 shares — an estimated $1K sold.

D.A. Davidson & Co first reported a position in SIOX in Q2 2015 and held it in 2 quarters. The position peaked at $2K in Q2 2015. 70 funds tracked by Wall St. Rank hold SIOX as of Q4 2015.

  • D.A. Davidson & Co reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • D.A. Davidson & Co sold 13 Sio Gene Therapies Inc. Common Stock shares in Q4 2015, an estimated $1K.
  • D.A. Davidson & Co first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 2 quarters.
  • D.A. Davidson & Co's Sio Gene Therapies Inc. Common Stock position peaked at $2K in Q2 2015.
  • 70 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2015.

Based on D.A. Davidson & Co's 13F filing for Q4 2015, filed 12 Feb 2016.